MIR-150 promotes prostate cancer stem cell development via suppressing p27Kip1

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 22, 2015, Pages 4344-4352

  Liu, D Z ^a   Zhang, H Y ^b   Long, X L ^a   Zou, S L ^a   Zhang, X Y ^a   Han, G Y ^c   Cui, Z G ^d  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Beijing Shouer Pharmaceutical Factory   (China)

^c XINXIANG MEDICAL UNIVERSITY   (China)

^d 306 HOSPITAL OF PLA   (China)

Author keywords

Cancer stem cell; miR 151; p27Kip1; Prostate cancer

Indexed keywords

CDKN1B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MICRORNA; MIRN150 MICRORNA, HUMAN; TUMOR MARKER;

ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CANCER STEM CELL; HEK293 CELL LINE; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HEK293 CELLS; HUMANS; MALE; MICRORNAS; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS;

EID: 84957974591     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. CARSON CC, 3RD. Carcinoma of the prostate: overview of the most common malignancy in men. N C Med J 2006; 67: 122-127.
2. TAO ZQ, SHI AM, WANG KX, ZHANG WD. Epidemiology of prostate cancer: current status. Eur Rev Med Pharmacol Sci 2015; 19: 805-812.
3. LEE JT, LEHMANN BD, TERRIAN DM, CHAPPELL WH, STIVALA F, LIBRA M, MARTELLI AM, STEELMAN LS, MCCUBREY JA. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008; 7: 1745-1762.
4. ALBERTI C. Prostate cancer: radioresistance molecular target-related markers and foreseeable modalities of radiosensitization. Eur Rev Med Pharmacol Sci 2014; 18: 2275-2282.
5. WU Y, SHAO N, SHEN ZX, LI Q, WANG Y, LI C, MA G, DONG J, LU XJ, FENG NH. The efficacy and safety of zibotentan in the treatment of castration-resistant prostate cancer: a meta-analysis. Eur Rev Med Pharmacol Sci 2014; 18: 3291-3296.
6. WANG X, KRUITHOF-DE JULIO M, ECONOMIDES KD, WALKER D, YU H, HALILI MV, HU YP, PRICE SM, ABATESHEN C, SHEN MM. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009; 461: 495-500.
7. WANG ZA, SHEN MM. Revisiting the concept of cancer stem cells in prostate cancer. Oncogene 2011; 30: 1261-1271.
8. LI T, SU Y, MEI Y, LENG Q, LENG B, LIU Z, STASS SA, JIANG F. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest 2010; 90: 234-244.
9. HURT EM, KAWASAKI BT, KLARMANN GJ, THOMAS SB, FARRAR WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008; 98: 756-765.
10. COLLINS AT, BERRY PA, HYDE C, STOWER MJ, MAITLAND NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-10951.
11. MIKI J, FURUSATO B, LI H, GU Y, TAKAHASHI H, EGAWA S, SESTERHENN IA, MCLEOD DG, SRIVASTAVA S, RHIM JS. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 2007; 67: 3153-3161.
12. LIU C, KELNAR K, LIU B, CHEN X, CALHOUN-DAVIS T, LI H, PATRAWALA L, YAN H, JETER C, HONORIO S, WIGGINS JF, BADER AG, FAGIN R, BROWN D, TANG DG. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011; 17: 211-215.
13. HSIEH IS, CHANG KC, TSAI YT, KE JY, LU PJ, LEE KH, YEH SD, HONG TM, CHEN YL. MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis 2013; 34: 530-538.
14. HUANG S, GUO W, TANG Y, REN D, ZOU X, PENG X. miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells. Oncol Rep 2012; 28: 1831-1837.
15. DEZHONG L, XIAOYI Z, XIANLIAN L, HONGYAN Z, GUOHUA Z, BO S, SHENGLEI Z, LIAN Z. miR-150 is a factor of survival in prostate cancer patients. J BUON 2015; 20: 173-179.
16. ISOBE T, HISAMORI S, HOGAN DJ, ZABALA M, HENDRICKSON DG, DALERBA P, CAI S, SCHEEREN F, KUO AH, SIKANDAR SS, LAM JS, QIAN D, DIRBAS FM, SOMLO G, LAO K, BROWN PO, CLARKE MF, SHIMONO Y. miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway. Elife 2014; 3.
17. POLYAK K, LEE MH, ERDJUMENT-BROMAGE H, KOFF A, ROBERTS JM, TEMPST P, MASSAGUE J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78: 59-66.
18. DE MARZO AM, MEEKER AK, EPSTEIN JI, COFFEY DS. Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol 1998; 153: 911-919.
19. FANG Z, ZHANG T, DIZEYI N, CHEN S, WANG H, SWANSON KD, CAI C, BALK SP, YUAN X. Androgen receptor enhances p27 degradation in prostate cancer cells through rapid and selective TORC2 activation. J Biol Chem 2012; 287: 2090-2098.
20. CHEN X, LIU B, LI Q, HONORIO S, LIU X, LIU C, MULTANI AS, CALHOUN-DAVIS T, TANG DG. Dissociated primary human prostate cancer cells coinjected with the immortalized Hs5 bone marrow stromal cells generate undifferentiated tumors in NOD/SCID-gamma mice. PLoS One 2013; 8: e56903.
21. DONTU G, ABDALLAH WM, FOLEY JM, JACKSON KW, CLARKE MF, KAWAMURA MJ, WICHA MS. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17: 1253-1270.
22. HUANG S, CHEN Y, WU W, OUYANG N, CHEN J, LI H, LIU X, SU F, LIN L, YAO Y. miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor. PLoS One 2013; 8: e80707.
23. WU Q, JIN H, YANG Z, LUO G, LU Y, LI K, REN G, SU T, PAN Y, FENG B, XUE Z, WANG X, FAN D. MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2. Biochem Biophys Res Commun 2010; 392: 340-345.
24. CAO M, HOU D, LIANG H, GONG F, WANG Y, YAN X, JIANG X, WANG C, ZHANG J, ZEN K, ZHANG CY, CHEN X. miR-150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signalling inhibitor 1. Eur J Cancer 2014; 50: 1013-1024.
25. DE MARZO AM, NELSON WG, MEEKER AK, COFFEY DS. Stem cell features of benign and malignant prostate epithelial cells. J Urol 1998; 160: 2381-2392.
26. SAID J. Biomarker discovery in urogenital cancer. Biomarkers 2005; 10 Suppl 1: S83-86.
27. GAO H, OUYANG X, BANACH-PETROSKY W, BOROWSKY AD, LIN Y, KIM M, LEE H, SHIH WJ, CARDIFF RD, SHEN MM, ABATE-SHEN C. A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A 2004; 101: 17204-17209.
28. ROY S, GU M, RAMASAMY K, SINGH RP, AGARWAL C, SIRIWARDANA S, SCLAFANI RA, AGARWAL R. p21/Cip1 and p27/Kip1 are essential molecular targets of inositol hexaphosphate for its antitumor efficacy against prostate cancer. Cancer Res 2009; 69: 1166-1173.
29. SHIU SY, LEUNG WY, TAM CW, LIU VW, YAO KM. Melatonin MT1 receptor-induced transcriptional up-regulation of p27(Kip1) in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NF-kappaB): potential implications on prostate cancer chemoprevention and therapy. J Pineal Res 2013; 54: 69-79.
30. Ouyang Y, Gao P, Zhu B, Chen X, Lin F, Wang X, Wei J, Zhang H. Downregulation of microRNA- 429 inhibits cell proliferation by targeting p27Kip1 in human prostate cancer cells. Mol Med Rep 2015; 11: 1435-1441.
31. Guo SL, Peng Z, Yang X, Fan KJ, Ye H, Li ZH, Wang Y, Xu XL, Li J, Wang YL, Teng Y, Yang X. miR-148a promoted cell proliferation by targeting p27 in gastric cancer cells. Int J Biol Sci 2011; 7: 567-574.
32. Wang B, Li W, Guo K, Xiao Y, Wang Y, Fan J. miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochem Biophys Res Commun 2012; 421: 4-8.